MR-Proadrenomedullin as biomarker of renal damage in urinary tract infection in children

Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no studies that analyze its utility in febrile urinary tract infection (fUTI) in children. An accurate biomarker would provide an early detection of p...

Full description

Saved in:

Bibliographic Details
Published in:	BMC pediatrics Vol. 21; no. 1; p. 292
Main Authors:	Peñalver Penedo, Rafael, Rupérez Lucas, Marta, Álvarez-Sala Walther, Luis Antonio, Torregrosa Benavent, Alicia, Casas Losada, María Luisa, Bañuelos Andrio, Luis, Rebolledo Poves, Ana Belén, Bueno Campaña, Mercedes
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 29-06-2021 BioMed Central BMC
Subjects:	Accuracy Adrenomedullin Antibiotics Biomarker Biomarkers Child Chronic illnesses Confidence intervals Creatinine Diagnosis Electrolytes Female Gene expression Health aspects Humans Kidney Kidney diseases Male Pediatric Pediatric research Pediatrics Peptide hormones Physiological aspects Plasma Proadrenomedullin Prognosis Prospective Studies Protein Precursors Renal scarring Risk factors Urinary tract diseases Urinary tract infection Urinary tract infections Urinary Tract Infections - diagnosis Urine Urogenital system Spain Proadrenomedullin Biomarker Urinary tract infection Pediatric Renal scarring
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no studies that analyze its utility in febrile urinary tract infection (fUTI) in children. An accurate biomarker would provide an early detection of patients with kidney damage, avoiding other invasive tests like renal scintigraphy scans. Our objective is to study the usefulness of MR-proADM as a biomarker of acute and chronic renal parenchymal damage in fUTI within the pediatric population. A prospective cohort study was conducted in pediatric patients with fUTI between January 2015 and December 2018. Plasma and urine MR-proADM levels were measured at admission in addition to other laboratory parameters. After confirmation of fUTI, renal scintigraphy scans were performed during the acute and follow-up stages. A descriptive study has been carried out and sensitivity, specificity and ROC curves for MR-proADM, C-reactive protein, and procalcitonin were calculated. 62 pediatric patients (34 female) were enrolled. Scintigraphy showed acute pyelonephritis in 35 patients (56.5%). Of those patients, the median of plasmatic MR-proADM (P-MR-proADM) showed no differences compared to patients without pyelonephritis. 7 patients (11.3%) developed renal scars (RS). Their median P-MR-proADM levels were 1.07 nmol/L (IQR 0.66-1.59), while in patients without RS were 0.48 nmol/L (0.43-0.63) (p < 0.01). The AUC in this case was 0.92 (95% CI 0.77-0.99). We established an optimal cut-off point at 0.66 nmol/L with sensitivity 83.3% and specificity 81.8%. MR-ProADM has demonstrated a poor ability to diagnose pyelonephritis in pediatric patients with fUTI. However, P-MR-proADM proved to be a very reliable biomarker for RS prediction.
AbstractList	Background Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no studies that analyze its utility in febrile urinary tract infection (fUTI) in children. An accurate biomarker would provide an early detection of patients with kidney damage, avoiding other invasive tests like renal scintigraphy scans. Our objective is to study the usefulness of MR-proADM as a biomarker of acute and chronic renal parenchymal damage in fUTI within the pediatric population. Methods A prospective cohort study was conducted in pediatric patients with fUTI between January 2015 and December 2018. Plasma and urine MR-proADM levels were measured at admission in addition to other laboratory parameters. After confirmation of fUTI, renal scintigraphy scans were performed during the acute and follow-up stages. A descriptive study has been carried out and sensitivity, specificity and ROC curves for MR-proADM, C-reactive protein, and procalcitonin were calculated. Results 62 pediatric patients (34 female) were enrolled. Scintigraphy showed acute pyelonephritis in 35 patients (56.5%). Of those patients, the median of plasmatic MR-proADM (P-MR-proADM) showed no differences compared to patients without pyelonephritis. 7 patients (11.3%) developed renal scars (RS). Their median P-MR-proADM levels were 1.07 nmol/L (IQR 0.66-1.59), while in patients without RS were 0.48 nmol/L (0.43-0.63) (p < 0.01). The AUC in this case was 0.92 (95% CI 0.77-0.99). We established an optimal cut-off point at 0.66 nmol/L with sensitivity 83.3% and specificity 81.8%. Conclusion MR-ProADM has demonstrated a poor ability to diagnose pyelonephritis in pediatric patients with fUTI. However, P-MR-proADM proved to be a very reliable biomarker for RS prediction. Keywords: Proadrenomedullin, Biomarker, Urinary tract infection, Pediatric, Renal scarring Abstract Background Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no studies that analyze its utility in febrile urinary tract infection (fUTI) in children. An accurate biomarker would provide an early detection of patients with kidney damage, avoiding other invasive tests like renal scintigraphy scans. Our objective is to study the usefulness of MR-proADM as a biomarker of acute and chronic renal parenchymal damage in fUTI within the pediatric population. Methods A prospective cohort study was conducted in pediatric patients with fUTI between January 2015 and December 2018. Plasma and urine MR-proADM levels were measured at admission in addition to other laboratory parameters. After confirmation of fUTI, renal scintigraphy scans were performed during the acute and follow-up stages. A descriptive study has been carried out and sensitivity, specificity and ROC curves for MR-proADM, C-reactive protein, and procalcitonin were calculated. Results 62 pediatric patients (34 female) were enrolled. Scintigraphy showed acute pyelonephritis in 35 patients (56.5%). Of those patients, the median of plasmatic MR-proADM (P-MR-proADM) showed no differences compared to patients without pyelonephritis. 7 patients (11.3%) developed renal scars (RS). Their median P-MR-proADM levels were 1.07 nmol/L (IQR 0.66–1.59), while in patients without RS were 0.48 nmol/L (0.43–0.63) (p < 0.01). The AUC in this case was 0.92 (95% CI 0.77–0.99). We established an optimal cut-off point at 0.66 nmol/L with sensitivity 83.3% and specificity 81.8%. Conclusion MR-ProADM has demonstrated a poor ability to diagnose pyelonephritis in pediatric patients with fUTI. However, P-MR-proADM proved to be a very reliable biomarker for RS prediction. BACKGROUNDMidregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no studies that analyze its utility in febrile urinary tract infection (fUTI) in children. An accurate biomarker would provide an early detection of patients with kidney damage, avoiding other invasive tests like renal scintigraphy scans. Our objective is to study the usefulness of MR-proADM as a biomarker of acute and chronic renal parenchymal damage in fUTI within the pediatric population. METHODSA prospective cohort study was conducted in pediatric patients with fUTI between January 2015 and December 2018. Plasma and urine MR-proADM levels were measured at admission in addition to other laboratory parameters. After confirmation of fUTI, renal scintigraphy scans were performed during the acute and follow-up stages. A descriptive study has been carried out and sensitivity, specificity and ROC curves for MR-proADM, C-reactive protein, and procalcitonin were calculated. RESULTS62 pediatric patients (34 female) were enrolled. Scintigraphy showed acute pyelonephritis in 35 patients (56.5%). Of those patients, the median of plasmatic MR-proADM (P-MR-proADM) showed no differences compared to patients without pyelonephritis. 7 patients (11.3%) developed renal scars (RS). Their median P-MR-proADM levels were 1.07 nmol/L (IQR 0.66-1.59), while in patients without RS were 0.48 nmol/L (0.43-0.63) (p < 0.01). The AUC in this case was 0.92 (95% CI 0.77-0.99). We established an optimal cut-off point at 0.66 nmol/L with sensitivity 83.3% and specificity 81.8%. CONCLUSIONMR-ProADM has demonstrated a poor ability to diagnose pyelonephritis in pediatric patients with fUTI. However, P-MR-proADM proved to be a very reliable biomarker for RS prediction. Background Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no studies that analyze its utility in febrile urinary tract infection (fUTI) in children. An accurate biomarker would provide an early detection of patients with kidney damage, avoiding other invasive tests like renal scintigraphy scans. Our objective is to study the usefulness of MR-proADM as a biomarker of acute and chronic renal parenchymal damage in fUTI within the pediatric population. Methods A prospective cohort study was conducted in pediatric patients with fUTI between January 2015 and December 2018. Plasma and urine MR-proADM levels were measured at admission in addition to other laboratory parameters. After confirmation of fUTI, renal scintigraphy scans were performed during the acute and follow-up stages. A descriptive study has been carried out and sensitivity, specificity and ROC curves for MR-proADM, C-reactive protein, and procalcitonin were calculated. Results 62 pediatric patients (34 female) were enrolled. Scintigraphy showed acute pyelonephritis in 35 patients (56.5%). Of those patients, the median of plasmatic MR-proADM (P-MR-proADM) showed no differences compared to patients without pyelonephritis. 7 patients (11.3%) developed renal scars (RS). Their median P-MR-proADM levels were 1.07 nmol/L (IQR 0.66–1.59), while in patients without RS were 0.48 nmol/L (0.43–0.63) (p < 0.01). The AUC in this case was 0.92 (95% CI 0.77–0.99). We established an optimal cut-off point at 0.66 nmol/L with sensitivity 83.3% and specificity 81.8%. Conclusion MR-ProADM has demonstrated a poor ability to diagnose pyelonephritis in pediatric patients with fUTI. However, P-MR-proADM proved to be a very reliable biomarker for RS prediction. Abstract Background Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no studies that analyze its utility in febrile urinary tract infection (fUTI) in children. An accurate biomarker would provide an early detection of patients with kidney damage, avoiding other invasive tests like renal scintigraphy scans. Our objective is to study the usefulness of MR-proADM as a biomarker of acute and chronic renal parenchymal damage in fUTI within the pediatric population. Methods A prospective cohort study was conducted in pediatric patients with fUTI between January 2015 and December 2018. Plasma and urine MR-proADM levels were measured at admission in addition to other laboratory parameters. After confirmation of fUTI, renal scintigraphy scans were performed during the acute and follow-up stages. A descriptive study has been carried out and sensitivity, specificity and ROC curves for MR-proADM, C-reactive protein, and procalcitonin were calculated. Results 62 pediatric patients (34 female) were enrolled. Scintigraphy showed acute pyelonephritis in 35 patients (56.5%). Of those patients, the median of plasmatic MR-proADM (P-MR-proADM) showed no differences compared to patients without pyelonephritis. 7 patients (11.3%) developed renal scars (RS). Their median P-MR-proADM levels were 1.07 nmol/L (IQR 0.66–1.59), while in patients without RS were 0.48 nmol/L (0.43–0.63) ( p < 0.01). The AUC in this case was 0.92 (95% CI 0.77–0.99). We established an optimal cut-off point at 0.66 nmol/L with sensitivity 83.3% and specificity 81.8%. Conclusion MR-ProADM has demonstrated a poor ability to diagnose pyelonephritis in pediatric patients with fUTI. However, P-MR-proADM proved to be a very reliable biomarker for RS prediction. Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no studies that analyze its utility in febrile urinary tract infection (fUTI) in children. An accurate biomarker would provide an early detection of patients with kidney damage, avoiding other invasive tests like renal scintigraphy scans. Our objective is to study the usefulness of MR-proADM as a biomarker of acute and chronic renal parenchymal damage in fUTI within the pediatric population. A prospective cohort study was conducted in pediatric patients with fUTI between January 2015 and December 2018. Plasma and urine MR-proADM levels were measured at admission in addition to other laboratory parameters. After confirmation of fUTI, renal scintigraphy scans were performed during the acute and follow-up stages. A descriptive study has been carried out and sensitivity, specificity and ROC curves for MR-proADM, C-reactive protein, and procalcitonin were calculated. 62 pediatric patients (34 female) were enrolled. Scintigraphy showed acute pyelonephritis in 35 patients (56.5%). Of those patients, the median of plasmatic MR-proADM (P-MR-proADM) showed no differences compared to patients without pyelonephritis. 7 patients (11.3%) developed renal scars (RS). Their median P-MR-proADM levels were 1.07 nmol/L (IQR 0.66-1.59), while in patients without RS were 0.48 nmol/L (0.43-0.63) (p < 0.01). The AUC in this case was 0.92 (95% CI 0.77-0.99). We established an optimal cut-off point at 0.66 nmol/L with sensitivity 83.3% and specificity 81.8%. MR-ProADM has demonstrated a poor ability to diagnose pyelonephritis in pediatric patients with fUTI. However, P-MR-proADM proved to be a very reliable biomarker for RS prediction. Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no studies that analyze its utility in febrile urinary tract infection (fUTI) in children. An accurate biomarker would provide an early detection of patients with kidney damage, avoiding other invasive tests like renal scintigraphy scans. Our objective is to study the usefulness of MR-proADM as a biomarker of acute and chronic renal parenchymal damage in fUTI within the pediatric population. A prospective cohort study was conducted in pediatric patients with fUTI between January 2015 and December 2018. Plasma and urine MR-proADM levels were measured at admission in addition to other laboratory parameters. After confirmation of fUTI, renal scintigraphy scans were performed during the acute and follow-up stages. A descriptive study has been carried out and sensitivity, specificity and ROC curves for MR-proADM, C-reactive protein, and procalcitonin were calculated. 62 pediatric patients (34 female) were enrolled. Scintigraphy showed acute pyelonephritis in 35 patients (56.5%). Of those patients, the median of plasmatic MR-proADM (P-MR-proADM) showed no differences compared to patients without pyelonephritis. 7 patients (11.3%) developed renal scars (RS). Their median P-MR-proADM levels were 1.07 nmol/L (IQR 0.66-1.59), while in patients without RS were 0.48 nmol/L (0.43-0.63) (p < 0.01). The AUC in this case was 0.92 (95% CI 0.77-0.99). We established an optimal cut-off point at 0.66 nmol/L with sensitivity 83.3% and specificity 81.8%. MR-ProADM has demonstrated a poor ability to diagnose pyelonephritis in pediatric patients with fUTI. However, P-MR-proADM proved to be a very reliable biomarker for RS prediction.
ArticleNumber	292
Audience	Academic
Author	Rupérez Lucas, Marta Peñalver Penedo, Rafael Bueno Campaña, Mercedes Torregrosa Benavent, Alicia Bañuelos Andrio, Luis Casas Losada, María Luisa Álvarez-Sala Walther, Luis Antonio Rebolledo Poves, Ana Belén
Author_xml	– sequence: 1 givenname: Rafael orcidid: 0000-0002-7594-225X surname: Peñalver Penedo fullname: Peñalver Penedo, Rafael email: rpenalver@saludcastillayleon.es organization: Servicio de Pediatría, Hospital Santa Bárbara de Soria, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain. rpenalver@saludcastillayleon.es – sequence: 2 givenname: Marta orcidid: 0000-0003-3881-0941 surname: Rupérez Lucas fullname: Rupérez Lucas, Marta organization: Servicio de Pediatría, Hospital Universitario Fundación Alcorcón, Madrid, Spain – sequence: 3 givenname: Luis Antonio orcidid: 0000-0003-1781-5364 surname: Álvarez-Sala Walther fullname: Álvarez-Sala Walther, Luis Antonio organization: Departamento de Medicina, Facultad de Medicina, Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón, IiSGM, Instituto de Investigaciones Sanitarias Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain – sequence: 4 givenname: Alicia surname: Torregrosa Benavent fullname: Torregrosa Benavent, Alicia organization: Servicio de Análisis Clínicos, Hospital Universitario Fundación Alcorcón, Madrid, Spain – sequence: 5 givenname: María Luisa surname: Casas Losada fullname: Casas Losada, María Luisa organization: Servicio de Análisis Clínicos, Hospital Universitario Fundación Alcorcón, Madrid, Spain – sequence: 6 givenname: Luis surname: Bañuelos Andrio fullname: Bañuelos Andrio, Luis organization: Servicio de Medicina Nuclear, Hospital Universitario Fundación Alcorcón, Madrid, Spain – sequence: 7 givenname: Ana Belén orcidid: 0000-0002-3151-7999 surname: Rebolledo Poves fullname: Rebolledo Poves, Ana Belén organization: Biobanco, Hospital Universitario Fundación Alcorcón, Madrid, Spain – sequence: 8 givenname: Mercedes orcidid: 0000-0001-6732-733X surname: Bueno Campaña fullname: Bueno Campaña, Mercedes organization: Servicio de Pediatría, Hospital Universitario Fundación Alcorcón, Madrid, Spain
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34187408$$D View this record in MEDLINE/PubMed
BookMark	eNptUttqFTEUHaRiL_oDPsiAIL5MzXWSeRFK8VKoKKLgW8gkO-fkmJm0yYzQvzfT08s5IiEk7LX2IntlHVcHYxyhql5idIqxbN9lTKQUDSK4bNHyhjypjjATuCGM4oOd-2F1nPMGISwka59Vh5RhKRiSR9WvL9-bbylqm2CMA9g5BD_WOte9j4NOvyHV0dUF1KG2etArqAs-Jz_qdFNPSZupFByYycdxgczah0XsefXU6ZDhxd15Uv38-OHH-efm8uuni_Ozy8bwjk2NRsYy4M44jh0XRtoOM2rAtC3FrgNkLRXaSa170gtTkB40SCFQJwynlJ5UF1tdG_VGXSVfXn2jovbqthDTSuk0eRNASbAMsZYRwQTjDvcttkJ0tBSEBMGL1vut1tXcFy8MjGXAsCe6j4x-rVbxj5KEIUpwEXh7J5Di9Qx5UoPPBkLQI8Q5K8JZ20mEUVeor_-hbuKcis0Li1PCMWHskbXSZYBidFwsX0TVWSsIEYh1pLBO_8Mqy8LgTQmN86W-1_Bmp2ENOkzrHMO8fGLeJ5It0aSYcwL3YAZGagmh2oZQlRCq2xCqpenVro0PLfepo38B1trXZw
CitedBy_id	crossref_primary_10_3390_children9081181 crossref_primary_10_3390_biomedicines11082306
Cites_doi	10.1016/j.jpurol.2019.09.010 10.1093/ndt/13.7.1686 10.1542/peds.2012-2408d 10.1016/j.clinbiochem.2009.01.002 10.1016/j.juro.2015.04.091 10.1016/j.remn.2016.05.006 10.1006/frne.1998.0164 10.1007/s00467-007-0465-7 10.1016/j.peptides.2013.08.001 10.1186/s12879-019-3789-6 10.1074/jbc.M007822200 10.1016/j.molimm.2015.06.006 10.1007/s00431-011-1614-3 10.1016/S0001-2998(99)80006-3 10.2174/187221412799015263 10.1007/s15010-013-0423-1 10.1111/j.1440-1797.2005.00468.x 10.1186/cc13064 10.1136/bmj.299.6701.703 10.3346/jkms.2020.35.e65 10.1097/01.mop.0000193276.39495.0d 10.1111/apa.14346 10.1001/archpedi.154.4.339 10.1155/2018/7908148 10.1016/j.rmed.2014.09.018 10.1016/j.clinbiochem.2010.12.012 10.1038/pr.2012.38 10.1007/BF00860755 10.1007/s00467-005-1895-8 10.1002/14651858.CD009185.pub2 10.1373/clinchem.2005.051110 10.1097/INF.0b013e31815e4122 10.1681/ASN.2008030287 10.1542/peds.2010-0685 10.1186/cc3885
ContentType	Journal Article
Copyright	COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021
Copyright_xml	– notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021
DBID	CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.1186/s12887-021-02765-2
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Publicly Available Content Database CrossRef MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1471-2431
EndPage	292
ExternalDocumentID	oai_doaj_org_article_8ed40464274745f1b61d779342778e75 A672270492 10_1186_s12887_021_02765_2 34187408
Genre	Research Support, Non-U.S. Gov't Journal Article
GeographicLocations	Spain
GeographicLocations_xml	– name: Spain
GroupedDBID	--- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABUWG ACGFO ACGFS ACIHN ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX CITATION AFGXO 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c594t-a0cd4e5fcf51f57c8d9143cec6631f9e0dd37af8aab2b7c3cebeae877097c5333
IEDL.DBID	RPM
ISSN	1471-2431
IngestDate	Tue Oct 22 15:06:22 EDT 2024 Tue Sep 17 20:41:32 EDT 2024 Fri Oct 25 01:37:33 EDT 2024 Thu Oct 10 17:01:49 EDT 2024 Tue Nov 19 21:12:30 EST 2024 Tue Nov 12 23:15:19 EST 2024 Tue Aug 20 22:12:52 EDT 2024 Thu Sep 12 18:17:03 EDT 2024 Sat Sep 28 08:18:53 EDT 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Proadrenomedullin Biomarker Urinary tract infection Pediatric Renal scarring
Language	English
License	Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c594t-a0cd4e5fcf51f57c8d9143cec6631f9e0dd37af8aab2b7c3cebeae877097c5333
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0003-3881-0941 0000-0002-3151-7999 0000-0001-6732-733X 0000-0002-7594-225X 0000-0003-1781-5364
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240321/
PMID	34187408
PQID	2553251244
PQPubID	42847
PageCount	1
ParticipantIDs	doaj_primary_oai_doaj_org_article_8ed40464274745f1b61d779342778e75 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8240321 proquest_miscellaneous_2546980109 proquest_journals_2553251244 gale_infotracmisc_A672270492 gale_infotracacademiconefile_A672270492 gale_healthsolutions_A672270492 crossref_primary_10_1186_s12887_021_02765_2 pubmed_primary_34187408
PublicationCentury	2000
PublicationDate	2021-06-29
PublicationDateYYYYMMDD	2021-06-29
PublicationDate_xml	– month: 06 year: 2021 text: 2021-06-29 day: 29
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London
PublicationTitle	BMC pediatrics
PublicationTitleAlternate	BMC Pediatr
PublicationYear	2021
Publisher	BioMed Central Ltd BioMed Central BMC
Publisher_xml	– name: BioMed Central Ltd – name: BioMed Central – name: BMC
References	P Caruhel (2765_CR33) 2009; 42 2765_CR7 L Bañuelos-Andrío (2765_CR12) 2017; 36 D Miguel (2765_CR31) 2011; 44 EH Garin (2765_CR10) 2007; 22 C Rey (2765_CR24) 2013; 17 JH Lee (2765_CR14) 2020; 35 2765_CR28 R Cavallazzi (2765_CR20) 2014; 108 RB Sim (2765_CR37) 2015; 68 2765_CR22 NP Goldraich (2765_CR8) 1995; 9 SH Jacobson (2765_CR4) 1989; 299 A Piepsz (2765_CR9) 1999; 29 R Pío (2765_CR17) 2001; 276 M Christ-Crain (2765_CR21) 2005; 9 S Kalman (2765_CR34) 2005; 10 NG Morgenthaler (2765_CR19) 2005; 51 N Shaikh (2765_CR1) 2008; 27 R Kannan (2765_CR26) 2018; 2018 RH Mak (2765_CR36) 2006; 18 N Shaikh (2765_CR3) 2010; 126 T Kitao (2765_CR15) 2015; 194 S Kalman (2765_CR38) 2005; 20 2765_CR39 MM Oh (2765_CR6) 2012; 171 2765_CR11 J Dötsch (2765_CR35) 1998; 13 ATA Elmouttaleb (2765_CR27) 2016; 6 2765_CR32 C Kosmeri (2765_CR2) 2019; 15 2765_CR16 BMY Cheung (2765_CR18) 2012; 6 JE Stalenhoef (2765_CR23) 2019; 19 2765_CR13 M Bueno Campaña (2765_CR25) 2018; 107 M Wennerström (2765_CR5) 2000; 154 S Gracia (2765_CR29) 2006; 26 2765_CR30
References_xml	– volume: 15 start-page: 598 issue: 6 year: 2019 ident: 2765_CR2 publication-title: J Pediatr Urol doi: 10.1016/j.jpurol.2019.09.010 contributor: fullname: C Kosmeri – volume: 13 start-page: 1686 issue: 7 year: 1998 ident: 2765_CR35 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/13.7.1686 contributor: fullname: J Dötsch – ident: 2765_CR11 doi: 10.1542/peds.2012-2408d – volume: 26 start-page: 658 issue: 6 year: 2006 ident: 2765_CR29 publication-title: Nefrologia. contributor: fullname: S Gracia – ident: 2765_CR30 – volume: 42 start-page: 725 issue: 7–8 year: 2009 ident: 2765_CR33 publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2009.01.002 contributor: fullname: P Caruhel – ident: 2765_CR7 – volume: 194 start-page: 766 issue: 3 year: 2015 ident: 2765_CR15 publication-title: J Urol doi: 10.1016/j.juro.2015.04.091 contributor: fullname: T Kitao – volume: 36 start-page: 2 issue: 1 year: 2017 ident: 2765_CR12 publication-title: Rev Esp Med Nucl Imagen Mol doi: 10.1016/j.remn.2016.05.006 contributor: fullname: L Bañuelos-Andrío – ident: 2765_CR16 doi: 10.1006/frne.1998.0164 – volume: 22 start-page: 1002 issue: 7 year: 2007 ident: 2765_CR10 publication-title: Pediatr Nephrol doi: 10.1007/s00467-007-0465-7 contributor: fullname: EH Garin – ident: 2765_CR39 doi: 10.1016/j.peptides.2013.08.001 – volume: 19 start-page: 1 issue: 1 year: 2019 ident: 2765_CR23 publication-title: BMC Infect Dis doi: 10.1186/s12879-019-3789-6 contributor: fullname: JE Stalenhoef – volume: 276 start-page: 12292 issue: 15 year: 2001 ident: 2765_CR17 publication-title: J Biol Chem doi: 10.1074/jbc.M007822200 contributor: fullname: R Pío – volume: 68 start-page: 45 issue: 1 year: 2015 ident: 2765_CR37 publication-title: Mol Immunol doi: 10.1016/j.molimm.2015.06.006 contributor: fullname: RB Sim – volume: 171 start-page: 565 issue: 3 year: 2012 ident: 2765_CR6 publication-title: Eur J Pediatr doi: 10.1007/s00431-011-1614-3 contributor: fullname: MM Oh – volume: 29 start-page: 160 issue: 2 year: 1999 ident: 2765_CR9 publication-title: Semin Nucl Med doi: 10.1016/S0001-2998(99)80006-3 contributor: fullname: A Piepsz – volume: 6 start-page: 4 issue: 1 year: 2012 ident: 2765_CR18 publication-title: Recent Pat Endocr Metab Immune Drug Discov doi: 10.2174/187221412799015263 contributor: fullname: BMY Cheung – ident: 2765_CR22 doi: 10.1007/s15010-013-0423-1 – volume: 6 start-page: 6 issue: 1 year: 2016 ident: 2765_CR27 publication-title: Am J Biochem contributor: fullname: ATA Elmouttaleb – volume: 10 start-page: 487 issue: 5 year: 2005 ident: 2765_CR34 publication-title: Nephrology. doi: 10.1111/j.1440-1797.2005.00468.x contributor: fullname: S Kalman – volume: 17 start-page: 1 issue: 5 year: 2013 ident: 2765_CR24 publication-title: Crit Care doi: 10.1186/cc13064 contributor: fullname: C Rey – volume: 299 start-page: 703 issue: 6701 year: 1989 ident: 2765_CR4 publication-title: Br Med J doi: 10.1136/bmj.299.6701.703 contributor: fullname: SH Jacobson – volume: 35 start-page: 1 issue: 10 year: 2020 ident: 2765_CR14 publication-title: J Korean Med Sci doi: 10.3346/jkms.2020.35.e65 contributor: fullname: JH Lee – volume: 18 start-page: 148 issue: 2 year: 2006 ident: 2765_CR36 publication-title: Curr Opin Pediatr doi: 10.1097/01.mop.0000193276.39495.0d contributor: fullname: RH Mak – volume: 107 start-page: 1467 issue: 8 year: 2018 ident: 2765_CR25 publication-title: Acta Paediatr doi: 10.1111/apa.14346 contributor: fullname: M Bueno Campaña – volume: 154 start-page: 339 issue: 4 year: 2000 ident: 2765_CR5 publication-title: Arch Pediatr Adolesc Med doi: 10.1001/archpedi.154.4.339 contributor: fullname: M Wennerström – volume: 2018 start-page: 1 year: 2018 ident: 2765_CR26 publication-title: Int J Pediatr doi: 10.1155/2018/7908148 contributor: fullname: R Kannan – volume: 108 start-page: 1569 issue: 11 year: 2014 ident: 2765_CR20 publication-title: Respir Med doi: 10.1016/j.rmed.2014.09.018 contributor: fullname: R Cavallazzi – volume: 44 start-page: 337 issue: 4 year: 2011 ident: 2765_CR31 publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2010.12.012 contributor: fullname: D Miguel – ident: 2765_CR32 doi: 10.1038/pr.2012.38 – volume: 9 start-page: 221 issue: 2 year: 1995 ident: 2765_CR8 publication-title: Pediatr Nephrol doi: 10.1007/BF00860755 contributor: fullname: NP Goldraich – volume: 20 start-page: 1111 issue: 8 year: 2005 ident: 2765_CR38 publication-title: Pediatr Nephrol doi: 10.1007/s00467-005-1895-8 contributor: fullname: S Kalman – ident: 2765_CR13 doi: 10.1002/14651858.CD009185.pub2 – volume: 51 start-page: 1823 issue: 10 year: 2005 ident: 2765_CR19 publication-title: Clin Chem doi: 10.1373/clinchem.2005.051110 contributor: fullname: NG Morgenthaler – volume: 27 start-page: 302 issue: 4 year: 2008 ident: 2765_CR1 publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e31815e4122 contributor: fullname: N Shaikh – ident: 2765_CR28 doi: 10.1681/ASN.2008030287 – volume: 126 start-page: 1084 issue: 6 year: 2010 ident: 2765_CR3 publication-title: Pediatrics. doi: 10.1542/peds.2010-0685 contributor: fullname: N Shaikh – volume: 9 start-page: 816 issue: 6 year: 2005 ident: 2765_CR21 publication-title: Crit Care doi: 10.1186/cc3885 contributor: fullname: M Christ-Crain
SSID	ssj0017846
Score	2.3406436
Snippet	Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no... Abstract Background Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However,... Background Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there... BACKGROUNDMidregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are... Abstract Background Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However,...
SourceID	doaj pubmedcentral proquest gale crossref pubmed
SourceType	Open Website Open Access Repository Aggregation Database Index Database
StartPage	292
SubjectTerms	Accuracy Adrenomedullin Antibiotics Biomarker Biomarkers Child Chronic illnesses Confidence intervals Creatinine Diagnosis Electrolytes Female Gene expression Health aspects Humans Kidney Kidney diseases Male Pediatric Pediatric research Pediatrics Peptide hormones Physiological aspects Plasma Proadrenomedullin Prognosis Prospective Studies Protein Precursors Renal scarring Risk factors Urinary tract diseases Urinary tract infection Urinary tract infections Urinary Tract Infections - diagnosis Urine Urogenital system
SummonAdditionalLinks	– databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LT94wDLeAA9oFDfbqYCyTkDhMEX2lTo9sA3FhmsaQuEV5Vdth_abvceC_x-5LVDtw4Vq7j9hxYtf2LwAnqCqHzqJUMVOyVBikCy5I5QNjp2RV3XDv8NUNfr_T3y4YJmc66otrwnp44F5wZzqGktNvHD2VqslclQWkSUUXUEfs0UtTPQZTQ_4AaVsdW2R0dbaiVZiMicsRKAzjuq7ZNtSh9f-_Jj_alOYFk492oMuXsDe4juK8_-R92IrtAexeD8nxV3B3_VP-WC4s92ZzTz2neVphV4Jb7LkKZykWjSAiPSTYv7SQCKLz33a7vBdrbpcSY21Wy6Sx0fs13F5e_Pp6JYeDE6RXdbmWNvWhjKrxjcoahV6HmtwiHz25F1lTxzSEAm2jrXW5Q08UF23UiGmNnvy_4g3stIs2vgOR-cJZ58nKXUqRXG5VEUghnMDzqrJ5Ap9HOZp_PT6G6eIKXZle6oakbjqpG-L-wqKeOBnburtAGjeDxs1TGk_gIyvK9I2ik4Wa8wrzHCniodecdhxsoyw9O7Qa0JAY7WrGeTTjJNvyc_I4Gcxg2ytDQVjBXmFZJvBpIvOdXK_WxsWGefhkTk47JvC2nzvToMlv4HMQdQI4m1Uzqcwp7Z_fHfK3ZvTEPHv_HGI8hBd5ZxCVzOsj2FkvN_EDbK_C5rizpQdjQB_L priority: 102 providerName: Directory of Open Access Journals
Title	MR-Proadrenomedullin as biomarker of renal damage in urinary tract infection in children
URI	https://www.ncbi.nlm.nih.gov/pubmed/34187408 https://www.proquest.com/docview/2553251244 https://search.proquest.com/docview/2546980109 https://pubmed.ncbi.nlm.nih.gov/PMC8240321 https://doaj.org/article/8ed40464274745f1b61d779342778e75
Volume	21
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCaWHopehq3dw1vXasCAHQY38UOWfOz6QC8Zij2A3gS9vBVY7MJJDvv3I2UrqLHbriYdx-JDpMmPAvggeGWE0SLlPuNpyYVLjTMu5dbR7JSsqhvCDt98E1_u5OUVjcnhEQsTmvatuT9rf6_O2vtfobfyYWXnsU9sfru8kDRELs_mM5hhbBhT9LF0IHBHjegYWc3X6IDRjqgTATMwauk6gH103XQUnZxsRmFm_7-e-dHWNG2bfLQPXT-Dp2MAyc6HP_ocnvj2EPaXY4n8CO6WX9PbvtOE0CZkPRV7WqbXjID21IvTs65hSMQfcXqF7oQhnb656_4P2xBoisUOrZZIEe79An5cX32_uEnH4xNSy-tyk-qFdaXnjW141nBhpasxOLLeYpCRNbVfOFcI3UitTW6ERYrx2kshFrWwGAUWL2Gv7Vr_GlhmC6ONRVs3C8zncs0L58pQxrO80nkCn-I6qodhSoYK2YWs1CAAhQJQQQAKuT_TUu84acJ1uND1P9UoZyU9PqDE7AjznZI3makyJ9CZ4AUhveAJnJKg1AAX3dmpOq9EngvMe_AxHwMHWSqtnh4BB_hKNPNqwnk84UQLs1NyVAY1WvhaYSpWUGxYlgm835HpTupaa323JR46n5OKjwm8GnRn99JRBRMQE62arMqUguYQ5n-P6v_mv-98Cwd5MIgqzetj2Nv0W_8OZmu3PQnfJE6CRf0FKRYjGw
link.rule.ids	230,315,729,782,786,866,887,2108,27935,27936,53803,53805
linkProvider	National Library of Medicine
linkToHtml	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9xADLYKlSiXvgtpaUmlSj1UYfOazOQIFLRVWYRaKnEbzSsFiU1QdvfQf197kqyIuHGNnY1m_Bh77c8D8IWzQnOteMRcwqKccRtpq23EjKXZKUlRVoQdnv7m51fi-wmNyWEDFsY37Rt9c1Dfzg_qm2vfW3k3N5OhT2xyMTsWNEQuTSYb8BTtNc6GJL0vHnA8Uwd8jCgmC3TBaEnUi4A5GDV1bcMWOm-6jE6MjiM_tf-hb753OI0bJ--dRKcvHrmGl_C8Dz3Dw478Cp64-jVszfri-hu4mv2KLtpGEbabMPlUJqpDtQgJok9dPG3YVCES8UesmqMjCpFO_9ar9l-4JLhVOPR21UQagOJv4c_pyeXxNOovXogMK_NlpGJjc8cqU7GkYtwIW2JYZZzB8CSpShdbm3FVCaV0qrlBinbKCc7jkhuMH7N3sFk3tduFMDGZVtqgl9AxZoKpYpm1uS8AGlaoNIBvw_7Lu26-hvR5iShkJziJgpNecBK5j0hEa06aje0fNO1f2e-uFA4_kGNehZlSzqpEF4nl6IbwAReOswD2ScCyA5quLVweFjxNOWZM-JmvnoNsnHZP9VAFXBJNyxpx7o040TbNmDwokex9w0JiEpdRVJnnAXxek-lN6nerXbMiHrrZk8qWAex0Orde9KC6AfCRNo52ZUxBJfSTw3ule__oN_fh2fRydibPfpz__ADbqTeqIkrLPdhctiv3ETYWdvXJ2-N_K343pQ
linkToPdf	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB7RIkW9lDc1FGokJA7I9XO99rG0jYogVcRD6m21L0MlYkdOcuDfM7N-qBY3uHrGsXbnsTOZ-WYB3nKWK64kD5iNWZAxbgJllAmYNjQ7Jc7LirDDV1_59U1xcUljcsarvlzTvla3p_Wv1Wl9-9P1Vq5XOhz6xMLl4rygIXJJHK5NFe7BfbTZiA2Jel9A4HiuDhiZIg836IbRmqgfAfMwauw6gBk6cLqQrpgcSW5y_9_--c4BNW2evHMazR_8xzoewmEfgvpnHcsjuGfrxzBb9EX2J3Cz-BIs20YSxpuw-VQuqn258QmqT908rd9UPhLxR4xcoUPykU7_2sv2t78l2JU_9HjVRBoA40_h-_zy2_lV0F_AEGhWZttARtpkllW6YnHFuC5MieGVthrDlLgqbWRMymVVSKkSxTVSlJW24DwqucY4Mn0G-3VT2yPwY50qqTR6CxVhRphIlhqTuUKgZrlMPHg_yECsuzkbwuUnRS464QkUnnDCE8j9gcQ0ctKMbPegaX-IfodFYfEDGeZXmDFlrIpVHhuO7ggf8MJy5sEJCVl0gNPR0sVZzpOEY-aEn3nnOMjWafdkD1nAJdHUrAnn8YQTbVRPyYMiid5HbAQmcylFl1nmwZuRTG9S31ttmx3x0A2fVL704Hmnd-OiB_X1gE80crIrUwoqopsg3ivei39-8wRmy4u5-Pzx-tNLOEicXeVBUh7D_rbd2VewtzG7184k_wD3Yjol
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MR-Proadrenomedullin+as+biomarker+of+renal+damage+in+urinary+tract+infection+in+children&rft.jtitle=BMC+pediatrics&rft.au=Pe%C3%B1alver+Penedo%2C+Rafael&rft.au=Rup%C3%A9rez+Lucas%2C+Marta&rft.au=%C3%81lvarez-Sala+Walther%2C+Luis+Antonio&rft.au=Torregrosa+Benavent%2C+Alicia&rft.date=2021-06-29&rft.eissn=1471-2431&rft.volume=21&rft.issue=1&rft.spage=292&rft.epage=292&rft_id=info:doi/10.1186%2Fs12887-021-02765-2&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2431&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2431&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2431&client=summon